NIH study shows mpox vaccine safe and effective in adolescents

A new clinical trial sponsored by the National Institutes of Health (NIH) has shown that the Jynneos (MVA-BN) vaccine is safe for adolescents and generates an antibody response similar to that in adults.

The findings address a knowledge gap in the use of the mpox vaccine in younger populations, especially those affected by the Clade I outbreak in Africa. Interim results from the trial were presented at IDWeek 2024 in Los Angeles.

The study evaluated the vaccine in adolescents aged 12 to 17, comparing it to results seen in adults aged 18 to 50. Researchers found that the vaccine was well-tolerated, with adverse events being comparable to those in adults.